ES2306459T3 - Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca). - Google Patents

Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca). Download PDF

Info

Publication number
ES2306459T3
ES2306459T3 ES97925934T ES97925934T ES2306459T3 ES 2306459 T3 ES2306459 T3 ES 2306459T3 ES 97925934 T ES97925934 T ES 97925934T ES 97925934 T ES97925934 T ES 97925934T ES 2306459 T3 ES2306459 T3 ES 2306459T3
Authority
ES
Spain
Prior art keywords
fudca
colonic
acid
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97925934T
Other languages
English (en)
Spanish (es)
Inventor
Joyce Corey Gibson
Leonhard Robert Capuano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2306459T3 publication Critical patent/ES2306459T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES97925934T 1996-05-23 1997-05-22 Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca). Expired - Lifetime ES2306459T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1820296P 1996-05-23 1996-05-23
US18202P 1996-05-23

Publications (1)

Publication Number Publication Date
ES2306459T3 true ES2306459T3 (es) 2008-11-01

Family

ID=21786767

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97925934T Expired - Lifetime ES2306459T3 (es) 1996-05-23 1997-05-22 Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca).

Country Status (10)

Country Link
US (1) US6426340B1 (enExample)
EP (1) EP0906106B1 (enExample)
JP (2) JP2000510858A (enExample)
AT (1) ATE394107T1 (enExample)
AU (1) AU3091597A (enExample)
CA (1) CA2253593C (enExample)
DE (1) DE69738667D1 (enExample)
ES (1) ES2306459T3 (enExample)
PT (1) PT906106E (enExample)
WO (1) WO1997044043A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338457C (en) * 1998-07-24 2009-11-17 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
EP1105141B1 (de) * 1998-08-06 2003-11-05 Wolfgang Stremmel Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung
PT1218889E (pt) * 1999-09-28 2010-03-08 Panacea Biotec Ltd Composições de libertação controlada compreendendo nimesulida
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EP1558763A4 (en) * 2002-11-01 2007-08-15 James Kaput IDENTIFICATION OF GENES ASSOCIATED WITH A DISEASE REGULATED BY A DIET
JP2010517941A (ja) * 2007-01-16 2010-05-27 ザ バーナム インスティテュート フォー メディカル リサーチ 結腸直腸癌の治療のための組成物および方法
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
CA3011595C (en) 2016-02-09 2024-01-02 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8825526D0 (en) * 1988-11-01 1988-12-07 Enzymatix Ltd Diagnosis
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps

Also Published As

Publication number Publication date
CA2253593A1 (en) 1997-11-27
PT906106E (pt) 2008-08-07
WO1997044043A1 (en) 1997-11-27
US6426340B1 (en) 2002-07-30
AU3091597A (en) 1997-12-09
ATE394107T1 (de) 2008-05-15
EP0906106B1 (en) 2008-05-07
DE69738667D1 (de) 2008-06-19
CA2253593C (en) 2008-07-08
EP0906106A1 (en) 1999-04-07
JP2000510858A (ja) 2000-08-22
JP2010059175A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
US6426340B1 (en) Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-FUDCA)
Halsted et al. Distribution of ethanol in the human gastrointestinal tract
ES2962302T3 (es) Tratamiento de la colestasis intrahepática y hepatopatías relacionadas
Resnick et al. Chemical and histologic demonstration of hydrochloric acid-induced release of serotonin from intestinal mucosa
JPH07508013A (ja) 医薬物用吸収促進剤としてのノルおよびホモ胆汁酸誘導体の使用
JP2002522357A5 (enExample)
JPH11506421A (ja) 腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用
PT1919458E (pt) Cisteamina revestida entericamente, cisteamina e seus derivados
Yeung et al. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm
JP2000507938A (ja) 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びｎｓａｉｄの組合せ
ES2288847T3 (es) Uso de inhibidores de endotoxina para el tratamiento de la caquexia.
KR100450293B1 (ko) 만성장염의치료에유용한알카노일l-카르니틴의용도
JPH04230223A (ja) ソマトスタチン吸収改善医薬組成物、その製法および用途
NO332773B1 (no) Anvendelse av epotilon B og farmasoytisk preparat inneholdende en slik forbindelse
Meeberg et al. Therapy with ursodeoxycholic acid in cholestatic liver disease
JP3455633B2 (ja) 潰瘍性大腸炎の予防又は治療剤
JP2007528361A (ja) 前立腺障害の治療および予防のための生薬組成物
Macaluso et al. The METEOR trial: the burial of methotrexate in ulcerative colitis?
Larrey et al. Acute colitis associated with prolonged administration of neuroleptics
JPH0224250B2 (enExample)
Allen et al. Chemical dissolution of bile duct stones
WO1993001817A1 (en) Antiviral compositions comprising fusidic acid, l-ascorbic acid and salicylic acid and derivatives
Balasubramanian et al. Pharmacokinetics of acrivastine after oral and colonic administration
AHONEN et al. Ketoconazole is Effective against the Chronic Mucocutaneous Candidosis of Autoimmune Polyendocrinopathy‐Candidosis‐Ectodermal Dystrophy (APECED)
US6677328B1 (en) Method for the prevention of colonic adenomas